ArticleScientific reports2025
Optimizing DCD donor liver function with resveratrol during machine perfusion.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive research has explored the use of machine perfusion to repair liver grafts, among these, interventions targeting mitochondrial repair are gaining attention due to its central role in ischemia-reperfusion injury and graft viability. Resveratrol, a mild natural polyphenol, is investigated here as a representative compound. Rat donor livers were subjected to 30 min of asystolic warm ischemia (DCD), followed by 2 h of either static cold storage (SCS), subnormothermic machine perfusion (SNMP) at 25 °C, or SNMP supplemented with resveratrol (SNMP-RES). All livers were subsequently reperfused under normothermic conditions for 1 h (NMP) with donor blood. Biochemical, transcriptomics RNA sequencing, inflammatory, and histological analyses were performed on perfusate samples and liver tissue biopsies. Resveratrol significantly enhanced the protective effects of SNMP, reducing perfusate AST (p = 0.03) and flavin mononucleotide (FMN) (p = 0.01). Resveratrol also decreased perfusate cytokine levels and improved tissue morphology. Transcriptomic analysis identified an upregulation of regenerative pathways using resveratrol, including Notch-signaling and Wnt signaling. The innate immune response was downregulated. This study represents the potential of FMN as a marker for liver quality during SNMP for the first time and demonstrates resveratrol's effects during SNMP. These findings encourage further exploration of mitochondrial-targeted preservation strategies and validate long-term benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.